Table 6 Factors that affects the diffusion of NCE products: Panel regression for the cardiovascular system (ATC C)
From: Differential diffusion of pharmaceutical innovations in a mixed market middle - income economy
Model 4 | Model 4(a) and Model 4(b) | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Â | Â | Â | Â | Â | Public | Private | ||||
Variable | Coefficient | Â | Standard Error | Variable | Coefficient | Â | Standard Error | Coefficient | Â | Standard Error |
Intercept | 0.587 | Â | (0.848) | Intercept | -4.564 | * | (2.015) | -0.303 | Â | (1.643) |
Drug characteristic | ||||||||||
 Ln price per DDD | -2.782 | *** | (0.703) | Ln price per DDD | -1.776 | * | (0.804) | -1.811 |  | (1.954) |
Structure and environment characteristics | ||||||||||
 Generic share (DDD) | 1.641 |  | (2.343) | Generic share (DDD) | 6.631 | ** | (1.865) | 16.893 | *** | (4.258) |
 Market concentration (HHI) | -0.082 |  | (1.068) | Market concentration (HHI) | 0.176 |  | (1.864) | 2.431 |  | (1.348) |
Year after registration | ||||||||||
 Year 1 | 2.036 | *** | (0.219) | Year 1 | 3.446 | *** | (0.509) | 2.200 | *** | (0.245) |
 Year 2 | 2.995 | *** | (0.252) | Year 2 | 4.639 | *** | (0.700) | 3.091 | *** | (0.222) |
 Year 3 | 3.289 | *** | (0.268) | Year 3 | 5.145 | *** | (0.874) | 3.502 | *** | (0.243) |
 Year 4 | 3.582 | *** | (0.296) | Year 4 | 5.543 | *** | (0.867) | 3.594 | *** | (0.238) |
 Year 5 | 4.068 |  | (0.266) | Year 5 | 6.322 | *** | (0.712) | 3.788 | *** | (0.224) |
R – squared | 0.170 |  |  | R – squared | 0.518 |  |  | 0.005 |  |  |
Corr (u_i, Xb) | -0.635 | Â | Â | Corr (u_i, Xb) | -0.541 | Â | Â | -0.755 | Â | Â |
Rho | 0.971 | Â | Â | Rho | 0.903 | Â | Â | 0.995 | Â | Â |
Number of observations | 142 | Â | Â | Number of observations | 65 | Â | Â | 77 | Â | Â |